Myulab Innovation obtains ENISA’s emerging company certification: what it really certifies

The word startup is used so often that it can sometimes be hard to know what lies behind it.

In Spain, however, there is a specific legal status: the emerging company certified under Law 28/2022, commonly known as the Startups Act.

Myulab Innovation, S.L., the company that develops Myukura, holds this certification issued by ENISA, Empresa Nacional de Innovación.

It is not a certification of a healthcare product, nor an assessment of the accuracy of our artificial intelligence.

It is an accreditation relating to the company itself, its innovative nature and its capacity for growth.

The distinction matters.

What the emerging company certification is

ENISA is the body responsible for managing the procedure by which a company can be formally recognised as an emerging company for the purposes of Law 28/2022.

The procedure includes submitting documentation, analysing the application and an administrative decision.

According to ENISA itself, processing is free of charge for the company.

The certification makes it possible to show that the company meets the conditions needed to benefit from the specific regime provided for by the law.

What ENISA assesses

To obtain this status, the company must meet a series of requirements.

Among them:

• being incorporated as a commercial company or cooperative;
• being within the age limits set by the regulations;
• having its registered office, corporate address or permanent establishment in Spain;
• having the percentage of staff required by law employed in Spain;
• not having distributed dividends;
• not being listed on a regulated market;
• staying below the established turnover limit;
• and developing a project considered innovative and with scalability potential.

The assessment, therefore, is not limited to checking the date the company was incorporated.

What it means for Myulab Innovation

For an early-stage technology company, the certification above all represents formal recognition that the project meets the conditions established by Spanish law for emerging companies.

Law 28/2022 also provides a set of specific measures for this type of company.

Among them are a reduced corporate income tax rate of 15% for the periods provided for by law, certain tax deferrals and various measures relating to investment and talent attraction.

The actual application of each benefit depends on the conditions set out in the regulations themselves.

What this certification does not mean

In a project related to healthcare technology, it is especially important not to confuse areas.

ENISA’s certification does not clinically validate Myukura.

Nor does it certify that a given artificial intelligence model is safe, that a medical function has been certified or that the product has gone through a healthcare regulatory process.

What it certifies is something else: that Myulab Innovation meets the legally established criteria to be considered an innovative and scalable emerging company.

These are different planes and we think it is important to explain them transparently.

Building a company and a product at the same time

Myukura is still in the development phase.

As the technology work advances, it is also necessary to build around the product a business structure able to sustain it.

ENISA’s certification thus adds to other recent milestones, such as our selection for the 8th MareNostrum Hackathon at the Barcelona Supercomputing Center and Andalusia’s ScaleUp 2026 programme.

They do not replace product development.

But they are part of something essential for a technology to move from prototype to sustainable company: building product, structure and ecosystem at the same time.

To learn about our approach to security, human oversight and AI governance, see also Myukura’s Trust Center and our Responsible AI page.